Clinical Trials Logo

Schizophrenia clinical trials

View clinical trials related to Schizophrenia.

Filter by:

NCT ID: NCT05115604 Completed - Schizophrenia Clinical Trials

Insomnia in the Patient With Schizophrenic Disorder: Evaluation of a CBT and Psychoeducational Intervention

Start date: April 8, 2021
Phase: N/A
Study type: Interventional

The study aims to evaluate the efficacy of a cognitive behavioural and psychoeducational intervention in patients with insomnia and diagnosed with a schizophrenic disorder.

NCT ID: NCT05111548 Completed - Schizophrenia Clinical Trials

Brain Stimulation and Cognitive Training - Efficacy

Start date: September 8, 2021
Phase: N/A
Study type: Interventional

People with serious mental illness often experience difficulties with thinking skills like memory. These difficulties can make it harder to perform day-to-day activities. The purpose of this study is to test whether combining a type of non-invasive brain stimulation with computerized cognitive exercises is helpful in improving a specific type of memory skill in people who have mental health conditions. The study is a randomized clinical trial, meaning that participants will be randomly assigned to receive either 'active' or 'inactive' brain stimulation. All participants will complete computerized cognitive exercises, also known as cognitive training. Overall, participants will be in the study for 6-8 weeks. The study involves 10 visits to the clinic over 2-4 weeks for cognitive training and either active or inactive brain stimulation. Participants will also complete paper-and-pencil assessments at the beginning and end of treatment, and one month after treatment ends.

NCT ID: NCT05110157 Recruiting - Schizophrenia Clinical Trials

Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia

Start date: November 29, 2021
Phase: Phase 3
Study type: Interventional

The primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.

NCT ID: NCT05109572 Completed - Schizophrenia Clinical Trials

The Impact of the Covid-19 Pandemic on Schizophrenia Patients Registered With the Community Mental Health Center

Start date: March 20, 2021
Phase:
Study type: Observational

This study aimed to examine the effect of the Covid-19 pandemic on schizophrenia patients registered to the Community Mental Health Center (CMHC) in terms of depression, suicide risk, and tendency to violence.

NCT ID: NCT05109065 Recruiting - Schizophrenia Clinical Trials

Peripheral Immune System in Individuals With Schizophrenia

Start date: March 1, 2021
Phase:
Study type: Observational

The investigators are seeking healthy volunteers and people with schizophrenia or schizoaffective disorder for a clinical study of the immune system in psychotic disorders. This is an observational study, to understand the ways in which the immune system may be contributing to the disease process.

NCT ID: NCT05106309 Completed - Schizophrenia Clinical Trials

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Start date: December 29, 2021
Phase: Phase 1
Study type: Interventional

A 2-part, crossover design, open-label treatment trial with 4 periods, 4 sequences (Part A) to evaluate MR formulations of CVL-231 and a 2 periods, 2 sequences (Part B) to understand effect of food on CVL-231 exposures from an MR formulation.

NCT ID: NCT05105542 Completed - Healthy Clinical Trials

M1 Schizophrenia PET Study

Start date: April 20, 2021
Phase: Phase 2
Study type: Interventional

This exploratory study seeks to examine M1 receptor availability in SZ patients and to relate M1 receptor availability to proximal and distal measures of cognitive performance, namely evoked ɣ oscillations in the EEG and verbal memory. Furthermore, the relationship between hippocampal [11C]EMO availability (BPND), evoked ɣ oscillations, verbal memory, and measures of illness severity will be explored.

NCT ID: NCT05103865 Completed - Clinical trials for Diagnosis, Dual (Psychiatry)

Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions

Start date: November 3, 2015
Phase: N/A
Study type: Interventional

Animal-assisted therapy (AAT) is a complementary intervention of therapy that has shown positive results in the treatment of various pathologies. This study assesses the viability of the implementation and the efectiveness of an AAT program in patients diagnosed with substance abuse disorder and associated mental disorders (dual pathology).

NCT ID: NCT05102929 Recruiting - Schizophrenia Clinical Trials

Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

REDOCS
Start date: November 5, 2021
Phase: N/A
Study type: Interventional

This study will investigate the effects of intermittent Theta Burst Stimulation (iTBS) on natural oscillatory frequency of the dorsolateral prefrontal cortex (DLPFC) and working memory in early-course schizophrenia (EC-SCZ). Transcranial magnetic stimulation (TMS) will be used to evoke oscillatory activity, and EEG will record the responses of EC-SCZ participants. A working memory task will also be incorporated in order to determine how DLPFC natural frequency (NF) is related to working memory performance. iTBS (active or sham) will be administered, then the oscillatory activity of DLPFC and working memory performance will be reassessed. The overarching goal is to determine whether iTBS can acutely enhance the oscillatory activity of the DLPFC and to evaluate the relationship between changes in the DLPFC and working memory performance.

NCT ID: NCT05100888 Enrolling by invitation - Schizophrenia Clinical Trials

Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms

tbTMS_SCH21
Start date: July 11, 2022
Phase: N/A
Study type: Interventional

The major target of the study is to confirm the safety and efficacy of our augmented protocol of theta-burst TMS in schizophrenia. Our aim is to confirm the beneficial effects of rTMS treatment on multiple aspects of the disorder such as (1) clinical aspect in terms of PANSS, (2) cognitive aspect such as emotion recognition (ER) and working memory (WM) / distractor filtering (DF) performance, and (3) neurobiology in terms of electrophysiology correlates of ER, WM and DF such as event related theta synchronization, resting state theta power, and network connectivity. Response prediction to (theta-burst) TB-rTMS will be the exploratory part of the study.